INFLUENCE OF DRUG DELIVERY SYSTEMS ON THE SAFETY AND EFFECTIVENESS PROFILE OF RIBAVIRIN
DOI:
https://doi.org/10.22159/ijap.2025v17i2.52864Keywords:
Ribavirin, Drug delivery systems, Excipients, Side effects, Hemolytic anemia, BioavailabilityAbstract
Ribavirin is an antiviral drug with a wide spectrum of pharmacological activity. The development of drug delivery systems that increase the safety and effectiveness of ribavirin has been the subject of scientific research for decades. The aim of this article is to examine the published information on this topic, evaluate it according to several criteria, and outline the primary perspectives on this subject within the fields of pharmacy and pharmacology. The results of the evaluation indicate that, despite the extensive and ongoing discourse surrounding the potential modifications to ribavirin within the international scientific community, the majority of publications adopt an illustrative approach. Many relevant and promising applied studies require further development, comprehensive biopharmaceutical indicator testing, rigorous clinical efficacy assessment, and a thorough evaluation of patient compliance.
References
Mejer N, Galli A, Ramirez S, Fahnøe U, Benfield T, Bukh J. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. Virology. 2020 Jan 15;540:132-40. doi: 10.1016/j.virol.2019.09.014, PMID 31778898.
Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C. Ribavirin for hepatitis E virus infection after organ transplantation: a large European retrospective multicenter study. Clin Infect Dis. 2020 Aug 22;71(5):1204-11. doi: 10.1093/cid/ciz953, PMID 31793638.
Salam AP, Duvignaud A, Jaspard M, Malvy D, Carroll M, Tarning J. Ribavirin for treating lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLOS Negl Trop Dis. 2022 Mar 30;16(3):e0010289. doi: 10.1371/journal.pntd.0010289, PMID 35353804, PMCID PMC9000057.
Eberhardt KA, Mischlinger J, Jordan S, Groger M, Gunther S, Ramharter M. Ribavirin for the treatment of lassa fever: a systematic review and meta-analysis. Int J Infect Dis. 2019 Oct;87:15-20. doi: 10.1016/j.ijid.2019.07.015, PMID 31357056.
Mayor J, Engler O, Rothenberger S. Antiviral efficacy of ribavirin and favipiravir against hantaan virus. Microorganisms. 2021 Jun 15;9(6):1306. doi: 10.3390/microorganisms9061306, PMID 34203936, PMCID PMC8232603.
Tejada S, Martinez Reviejo R, Karakoc HN, Pena Lopez Y, Manuel O, Rello J. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis. Adv Ther. 2022 Sep;39(9):4037-51. doi: 10.1007/s12325-022-02256-5, PMID 35876973.
Poulakou G, Barakat M, Israel RJ, Bacci MR, Virazole Collaborator Group for COVID-19 Respiratory Distress. Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: an open-label trial. Clin Transl Sci. 2023 Jan;16(1):165-74. doi: 10.1111/cts.13436, PMID 36326174, PMCID PMC9841304.
Unal MA, Bitirim CV, Summak GY, Bereketoglu S, Cevher Zeytin I, Besbinar O. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro. Can J Physiol Pharmacol. 2021 May;99(5):449-60. doi: 10.1139/cjpp-2020-0734, PMID 33689451.
Janowski AB, Dudley H, Wang D. Antiviral activity of ribavirin and favipiravir against human astroviruses. J Clin Virol. 2020 Feb;123:104247. doi: 10.1016/j.jcv.2019.104247, PMID 31864069, PMCID PMC7034780.
Huq S, Casaos J, Serra R, Peters M, Xia Y, Ding AS. Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma. Mol Cancer Ther. 2020 Sep;19(9):1797-808. doi: 10.1158/1535-7163.MCT-19-0572, PMID 32606016.
Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R. The use of ribavirin as an anticancer therapeutic: will it go viral? Mol Cancer Ther. 2019 Jul;18(7):1185-94. doi: 10.1158/1535-7163.MCT-18-0666, PMID 31263027.
Zhu S, Han X, Yang R, Tian Y, Zhang Q, Wu Y. Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF/MS. Chem Biol Interact. 2023 Jan 25;370:110305. doi: 10.1016/j.cbi.2022.110305, PMID 36529159.
Burman B, Drutman SB, Fury MG, Wong RJ, Katabi N, Ho AL. Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Oral Oncol. 2022 May;128:105806. doi: 10.1016/j.oraloncology.2022.105806, PMID 35339025, PMCID PMC9788648.
Wambecke A, Laurent Issartel C, Leroy Dudal J, Giffard F, Cosson F, Lubin Germain N. Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. PLOS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860, PMID 31825993, PMCID PMC6905583.
Zhang Q, Yang R, Tian Y, Ge S, Nan X, Zhu S. Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5. Basic Clin Pharmacol Toxicol. 2022 Jul;131(1):18-33. doi: 10.1111/bcpt.13736, PMID 35470570.
Petkovic B, Kesic S, Pesic V. Critical view on the usage of ribavirin in already existing psychostimulant-use disorder. Curr Pharm Des. 2020;26(4):466-84. doi: 10.2174/1381612826666200115094642, PMID 31939725, PMCID PMC8383468.
Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009 Feb;50(2):402-11. doi: 10.1016/j.jhep.2008.11.006, PMID 19091439.
Shiffman ML. What future for ribavirin? Liver Int. 2009 Jan;29 Suppl 1:68-73. doi: 10.1111/j.1478-3231.2008.01936.x, PMID 19207968.
Barrail Tran A, Goldwirt L, Gele T, Laforest C, Lavenu A, Danjou H. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Eur J Clin Pharmacol. 2019 Nov;75(11):1555-63. doi: 10.1007/s00228-019-02725-x, PMID 31384986.
Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6. doi: 10.1128/AAC.43.10.2451, PMID 10508023, PMCID PMC89499.
Chen R, Wang T, Song J, Pu D, He D, Li J. Antiviral drug delivery system for enhanced bioactivity, better metabolism and pharmacokinetic characteristics. Int J Nanomedicine. 2021 Jul 22;16:4959-84. doi: 10.2147/IJN.S315705, PMID 34326637, PMCID PMC8315226.
Guo H, Sun S, Yang Z, Tang X, Wang Y. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect. J Control Release. 2015 Jul 10;209:27-36. doi: 10.1016/j.jconrel.2015.04.016, PMID 25883028.
Elberry MH, Darwish NH, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J. 2017 May 2;14(1):88. doi: 10.1186/s12985-017-0753-1, PMID 28464951, PMCID PMC5414367.
Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for hepatitis C virus. Nanomedicine (Lond). 2019 Jun;14(11):1471-91. doi: 10.2217/nnm-2018-0348, PMID 31166139.
Nader K, Shetta A, Saber S, Mamdouh W. The potential of carbon-based nanomaterials in hepatitis C virus treatment: a review of carbon nanotubes, dendrimers and fullerenes. Discov Nano. 2023 Sep 16;18(1):116. doi: 10.1186/s11671-023-03895-5, PMID 37715929, PMCID PMC10505122.
Di Stefano G, Busi C, Mattioli A, Fiume L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. Biochem Pharmacol. 1995 Jun 16;49(12):1769-75. doi: 10.1016/0006-2952(95)00020-z, PMID 7541203.
Fiume L, Busi C, Di Stefano GS, Mattioli A. Targeting of antiviral drugs to the liver using glycoprotein carriers. Adv Drug Deliv Rev. 1994;14(1):51-65. doi: 10.1016/0169-409X(94)90005-1.
Dong Z, Li Q, Guo D, Shu Y, Polli JE. Synthesis and evaluation of bile acid-ribavirin conjugates as prodrugs to target the liver. J Pharm Sci. 2015 Sep;104(9):2864-76. doi: 10.1002/jps.24375, PMID 25645375, PMCID PMC4522399.
Hashim F, El-Ridy M, Nasr M, Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 2010 Jul;17(5):282-7. doi: 10.3109/10717541003706257, PMID 20350052.
Schekman R, Singer SJ. Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans. Proc Natl Acad Sci USA. 1976;73(11):4075-9. doi: 10.1073/pnas.73.11.4075.
Rothen Rutishauser BM, Schurch S, Haenni B, Kapp N, Gehr P. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol. 2006;40(14):4353-9. doi: 10.1021/es0522635, PMID 16903270.
Abo Zeid Y, Irving W, Thomson B, Mantovani G, Garnett M. P19: ribavirin-boronic acid loaded nanoparticles: a possible route to improve hepatitis C treatment. J Viral Hepat. 2013;20(s3):26-7. doi: 10.1111/jvh.12166_18.
Ishihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci. 2014;103(12):4005-11. doi: 10.1002/jps.24219, PMID 25335768.
Virovic L, Wu CH, Konishi M, Wu GY, Wu GY. Novel delivery methods for treatment of viral hepatitis: an update. Expert Opin Drug Deliv. 2005 Jul;2(4):707-17. doi: 10.1517/17425247.2.4.707, PMID 16296795.
Wohl BM, Smith AA, Jensen BE, Zelikin AN. Macromolecular (pro) drugs with concurrent direct activity against the hepatitis C virus and inflammation. J Control Release. 2014 Dec 28;196:197-207. doi: 10.1016/j.jconrel.2014.09.032, PMID 25451544.
Chiani E, Beaucamp A, Hamzeh Y, Azadfallah M, Thanusha AV, Collins MN. Synthesis and characterization of gelatin/lignin hydrogels as quick release drug carriers for ribavirin. Int J Biol Macromol. 2023 Jan 1;224:1196-205. doi: 10.1016/j.ijbiomac.2022.10.205, PMID 36309240.
Kende M, Alving CR, Rill WL, Swartz GM Jr, Canonico PG. Enhanced efficacy of liposome-encapsulated ribavirin against rift valley fever virus infection in mice. Antimicrob Agents Chemother. 1985 Jun;27(6):903-7. doi: 10.1128/AAC.27.6.903, PMID 4026264, PMCID PMC180183.
Bialasek M, Kubiak M, Gorczak M, Braniewska A, Kucharzewska Siembieda P, Krol M. Exploiting iron-binding proteins for drug delivery. J Physiol Pharmacol. 2019 Oct;70(5). doi: 10.26402/jpp.2019.5.03, PMID 31889039.
Brookes S, Biessels P, Ng NF, Woods C, Bell DN, Adamson G. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery. Bioconjug Chem. 2006 Mar-Apr;17(2):530-7. doi: 10.1021/bc0503317, PMID 16536487.
Levy GA, Adamson G, Phillips MJ, Scrocchi LA, Fung L, Biessels P. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology. 2006 Mar;43(3):581-91. doi: 10.1002/hep.21072, PMID 16496340, PMCID PMC7165489.
Riber CF, Hinton TM, Gajda P, Zuwala K, Tolstrup M, Stewart C. Macromolecular prodrugs of ribavirin: structure-function correlation as inhibitors of influenza infectivity. Mol Pharm. 2017 Jan 3;14(1):234-41. doi: 10.1021/acs.molpharmaceut.6b00826, PMID 28043136.
Shigeta S, Mori S, Watanabe J, Soeda S, Takahashi K, Yamase T. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Chemother. 1997 Jul;41(7):1423-7. doi: 10.1128/AAC.41.7.1423, PMID 9210659, PMCID PMC163933.
Gangemi JD, Nachtigal M, Barnhart D, Krech L, Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis. 1987 Mar;155(3):510-7. doi: 10.1093/infdis/155.3.510, PMID 3805775.
Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van den Berg F. A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19, PMID 32071044, PMCID PMC7179635.
Ibrahim MM, Maria DN, Wang X, Simpson RN, Hollingsworth TJ, Jablonski MM. Enhanced corneal penetration of a poorly permeable drug using bioadhesive multiple microemulsion technology. Pharmaceutics. 2020 Jul 26;12(8):704. doi: 10.3390/pharmaceutics12080704, PMID 32722550, PMCID PMC7463957.
Li X, Pan W, Ju C, Liu Z, Pan H, Zhang H. Evaluation of pharmasolve corneal permeability enhancement and its irritation on rabbit eyes. Drug Deliv. 2009 May;16(4):224-9. doi: 10.1080/10717540902850567, PMID 19514982.
Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci. 2011 Aug;100(8):3186-95. doi: 10.1002/jps.22540, PMID 21416467.
Lai CH, Yang YH, Chen PC, King YC, Liu CY. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study. Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):191-8. doi: 10.1002/pds.4363, PMID 29210149.
Elgouhary SM, Said Ahmed KE, Mowafy MA. Anatomical and functional retinal complications of combined sofosbuvir and ribavirin therapy in patients with chronic hepatitis C virus. Ophthalmic Surg Lasers Imaging Retina. 2019 Jan 1;50(1):39-41. doi: 10.3928/23258160-20181212-06, PMID 30640394.
Abd Elaziz MS, Nada AS, ElSayed SH, Nasr GS, Zaky AG. Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients. Int Ophthalmol. 2020 May;40(5):1245-51. doi: 10.1007/s10792-020-01290-y, PMID 31965393.
Jeulin H, Venard V, Carapito D, Finance C, Kedzierewicz F. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res. 2009 Mar;81(3):261-6. doi: 10.1016/j.antiviral.2008.12.006, PMID 19133295.
Sengupta S, Paul P, Mukherjee B, Gaonkar RH, Debnath MC, Chakraborty R. Peripheral nerve targeting by procaine-conjugated ribavirin-loaded dual drug nanovesicle. Nanomedicine (Lond). 2018 Dec;13(23):3009-23. doi: 10.2217/nnm-2018-0192, PMID 30507340.
Colombo G, Lorenzini L, Zironi E, Galligioni V, Sonvico F, Balducci AG. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011 Dec;92(3):408-14. doi: 10.1016/j.antiviral.2011.09.012, PMID 22001322.
Giuliani A, Balducci AG, Zironi E, Colombo G, Bortolotti F, Lorenzini L. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv. 2018 Nov;25(1):376-87. doi: 10.1080/10717544.2018.1428242, PMID 29382237, PMCID PMC6058489.
Vasa DM, Bakri Z, Donovan MD, O’Donnell LA, Wildfong PL. Evaluation of ribavirin-poloxamer microparticles for improved intranasal absorption. Pharmaceutics. 2021 Jul 23;13(8):1126. doi: 10.3390/pharmaceutics13081126, PMID 34452087, PMCID PMC8399989.
Loginova SJ, Shchukina VN, Borisevich SV. The modern state of prevention and treatment of chikungunya fever. Jour Antibiot Chemother. 2020;65(3-4):45-53. doi: 10.37489/0235-2990-2020-65-3-4-45-53.
Zhurkin MA, Ivanov VV, Kharitonov MA, Saluchov VV, Zhogolev KD, Zhogolev SD. The use of ribavirinum in complex therapy of virus-bacterial pneumonia. “Russian-Chinese scientific-practical conference on medical microbiology and clinical mycology (ХIХ kashkinskiye readings). Theses of reports” Problems of Medical Mycology. 2016;18(2):34-131.
Shilovskiy IP, Yumashev KV, Kozhikhova KV, Vishniakova LI, Smirnov VV, Gudima GO. A synthetic peptide mimicking the antigenic site of F protein suppresses of respiratory syncytial virus infection in vitro. Immunologiya. 2023;44(2):134-46. doi: 10.33029/0206-4952-2023-44-2-134-146.
Postnov VN, Naumysheva EB, Korolev DV, Galagudza MM. Nanoscale carriers for drug delivery//Biotechnosphere. 2013;6(30).
Chekhonin VP, Merkulov VA, Kuznetsov DA, Petrov AA, Pavlyuk AS. Prospects for the application of nanobiotechnology in medicine. Bulletin of Russian State Medical University; 2009. Available from: https://cyberleninka.ru/article/n/perspektivy-primeneniya-nanobiotehnologii-v-meditsine [Last accessed on 22 Jan 2025]
Yamansarov EY, Petrov RA, Petrov SA, Saltykova IV, Ondar EE, Kislyakov IV. Low-molecular glycoconjugates antiviral drug ribavirin with galactosamine derivatives-a new approach to targeted therapy of liver diseases. Russian Biotherapeutic Journal; 2017. Available from: https://cyberleninka.ru/article/n/nizkomolekulyarnye-glikokonyugaty-protivovirusnogo-preparata-ribavirin-s-proizvodnymi-galaktozamina-novyy-podhod-adresnoy-terapii. [Last accessed on 31 Mar 2024].
Bakhrushina EO, Ivkina AS, Tabanskaya TV. Evaluation of biopharmaceutical indicators of a new intranasal antiviral drug based on in situ system//Health and Education in the XXI century. Vol. 4; 2023. Available from: https://cyberleninka.ru/article/n/otsenka-biofarmatsevticheskih-pokazateley-novogo-intranazalnogo-protivovirusnogo-preparata-na-osnove-in-situ-sistemy. [Last accessed on 31 Mar 2024].
Usova SV, Targonsky SN, Zemskova LN, Zmyzgova AV, Isaeva NP, Isaeva NP. Experience with a new regimen for the treatment of chronic viral hepatitis using liposomal form of ribavirin. Vol. 4; 2012. Available from: https://cyberleninka.ru/article/n/opyt-primeneniya-novoy-shemy-lecheniya-hronicheskogo-virusnogo-gepatita-s-s-ispolzovaniem-liposomalnoy-formy-ribavirina. [Last accessed on 31 Mar 2024].
Glotova TI, Nikonova AA, Glotov AG. Antiviral compounds and drugs effective against bovine viral diarrhea virus//voprosyvirosologii. Vol. 5; 2017. Available from: https://cyberleninka.ru/article/n/protivovirusnye-soedineniya-i-preparaty-effektivnye-v-otnoshenii-virusa-virusnoy-diarei-krupnogo-rogatogo-skota. [Last accessed on 31 Mar 2024].
Mendez R. Sonication-based basic protocol for liposome synthesis. Methods Mol Biol. 2023;2625:365-70. doi: 10.1007/978-1-0716-2966-6_31, PMID 36653658.
Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent progress in bioconjugation strategies for liposome-mediated drug delivery. Molecules. 2020 Dec 1;25(23):5672. doi: 10.3390/molecules25235672, PMID 33271886, PMCID PMC7730700.
Wang Y. Liposome as a delivery system for the treatment of biofilm-mediated infections. J Appl Microbiol. 2021 Dec;131(6):2626-39. doi: 10.1111/jam.15053, PMID 33650748.
Gorain B, Al-Dhubiab BE, Nair A, Kesharwani P, Pandey M, Choudhury H. Multivesicular liposome: a lipid-based drug delivery system for efficient drug delivery. Curr Pharm Des. 2021;27(43):4404-15. doi: 10.2174/1381612827666210830095941, PMID 34459377.
Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021 Sep;176:113851. doi: 10.1016/j.addr.2021.113851, PMID 34224787.
Lima PH, Butera AP, Cabeça LF, Ribeiro Viana RM. Liposome surface modification by phospholipid chemical reactions. Chem Phys Lipids. 2021 Jul;237:105084. doi: 10.1016/j.chemphyslip.2021.105084, PMID 33891960.
Meng Y, Niu X, Li G. Liposome nanoparticles as a novel drug delivery system for therapeutic and diagnostic applications. Curr Drug Deliv. 2022;20(1):41-56. doi: 10.2174/1567201819666220324093821, PMID 35331112.
Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020 Dec;30(4):336-65. doi: 10.1080/08982104.2019.1668010, PMID 31558079.
Gan Y, Yu Y, Xu H, Piao H. Liposomal nanomaterials: a rising star in glioma treatment. Int J Nanomedicine. 2024 Jul 5;19:6757-76. doi: 10.2147/IJN.S470478, PMID 38983132, PMCID PMC11232959.
Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154-155:102-22. doi: 10.1016/j.addr.2020.07.002, PMID 32650041.
Guimaraes D, Cavaco Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021 May 15;601:120571. doi: 10.1016/j.ijpharm.2021.120571, PMID 33812967.
Inal O, Amasya G, Sezgin Bayindir Z, Yuksel N. Development and quality assessment of glutathione tripeptide loaded niosome containing carbopol emulgels as nanocosmeceutical formulations. Int J Biol Macromol. 2023 Jun 30;241:124651. doi: 10.1016/j.ijbiomac.2023.124651, PMID 37119885.
Farmoudeh A, Akbari J, Saeedi M, Ghasemi M, Asemi N, Nokhodchi A. Methylene blue-loaded niosome: preparation, physicochemical characterization, and in vivo wound healing assessment. Drug Deliv Transl Res. 2020 Oct;10(5):1428-41. doi: 10.1007/s13346-020-00715-6, PMID 32100265, PMCID PMC7447683.
Kheilnezhad B, Hadjizadeh A. Factors affecting the penetration of niosome into the skin, their laboratory measurements and dependency to the niosome composition: a review. Curr Drug Deliv. 2021;18(5):555-69. doi: 10.2174/1567201817999200820161438, PMID 32842940.
Barani M, Paknia F, Roostaee M, Kavyani B, Kalantar Neyestanaki D, Ajalli N. Niosome as an effective nanoscale solution for the treatment of microbial infections. BioMed Res Int. 2023 Aug 16;2023:9933283. doi: 10.1155/2023/9933283, PMID 37621700, PMCID PMC10447041.
Lai X, Chow SH, Le Brun AP, Muir BW, Bergen PJ, White J. Polysaccharide-targeting lipid nanoparticles to kill gram-negative bacteria. Small. 2024 Feb;20(6):e2305052. doi: 10.1002/smll.202305052, PMID 37798622.
Rezaei H, Iranbakhsh A, Sepahi AA, Mirzaie A, Larijani K. Formulation, preparation of niosome loaded zinc oxide nanoparticles and biological activities. Sci Rep. 2024 Jul 19;14(1):16692. doi: 10.1038/s41598-024-67509-5, PMID 39030347, PMCID PMC11271597.
Hedayati Ch M, Abolhassani Targhi A, Shamsi F, Heidari F, Salehi Moghadam Z, Mirzaie A. Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. J Biomed Mater Res A. 2021 Jun;109(6):966-80. doi: 10.1002/jbm.a.37086, PMID 32865883.
Rahmati M, Babapoor E, Dezfulian M. Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant klebsiella pneumoniae strains. World J Microbiol Biotechnol. 2022 Oct 3;38(12):230. doi: 10.1007/s11274-022-03405-2, PMID 36184645, PMCID PMC9527143.
Ergin AD, Oltulu C, Turker NP, Demirbolat GM. In vitro hepatotoxicity evaluation of methotrexate-loaded niosome formulation: fabrication, characterization and cell culture studies. Turk J Med Sci. 2023 Aug;53(4):872-82. doi: 10.55730/1300-0144.5651, PMID 38031943, PMCID PMC10760534.
Salehi S, Nourbakhsh MS, Yousefpour M, Rajabzadeh G, Sahab Negah S. Chitosan-coated niosome as an efficient curcumin carrier to cross the blood-brain barrier: an animal study. J Liposome Res. 2022 Sep;32(3):284-92. doi: 10.1080/08982104.2021.2019763, PMID 34957899.
Sharma S, Kumari N, Garg D, Chauhan S. A compendium of bioavailability enhancement via niosome technology. Pharm Nanotechnol. 2023;11(4):324-38. doi: 10.2174/2211738511666230309104323, PMID 36892113.
Obeid MA, Teeravatcharoenchai T, Connell D, Niwasabutra K, Hussain M, Carter K. Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses. J Liposome Res. 2021 Jun;31(2):195-202. doi: 10.1080/08982104.2020.1768110, PMID 32396752.
Tao R, Liu L, Xiong Y, Zhang Q, Lv X, He L. Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole. Drug Deliv Transl Res. 2023 Nov;13(11):2819-33. doi: 10.1007/s13346-023-01349-0, PMID 37160629.
Kalebar RV, Gajare P, Mamle DSN, Kalebar VU, Aladakatti RH. Synergistic drug compatibility of sumatriptan succinate and metoclopramide hydrochloride (in situ gel formulations) for nasal drug release optimization. Asian J Pharm Clin Res. 2024 Mar 7:132-8.
Singh M, Dev D. Acacia catachu gum in situ forming gels with prolonged retention time for ocular drug delivery. Asian J Pharm Clin Res. 2022 Sep 7:33-40. doi: 10.22159/ajpcr.2022.v15i9.45269.
Ambikar RB, Bhosale AV. Development and characterization of diclofenac sodium loaded eudragit RS100 polymeric microsponge incorporated into in situ gel for ophthalmic drug delivery system. Int J Pharm Pharm Sci. 2021 Sep 1:63-9. doi: 10.22159/ijpps.2021v13i9.42405.
Reddy MS, Begum Z. Formulation and in vitro evaluation of gastro retentive in-situ floating gels of telmisartan cubosomes. Int J Curr Pharm Sci. 2022 Jan 15:44-53. doi: 10.22159/ijcpr.2022v14i1.44111.
Ourani Pourdashti S, Mirzaei E, Heidari R, Ashrafi H, Azadi A. Preparation and evaluation of niosomal chitosan-based in situ gel formulation for direct nose-to-brain methotrexate delivery. Int J Biol Macromol. 2022 Jul 31;213:1115-26. doi: 10.1016/j.ijbiomac.2022.06.031, PMID 35691430.
Mohanty D, Alsaidan OA, Zafar A, Dodle T, Gupta JK, Yasir M. Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: optimization, in vitro, and preclinical evaluation. Pharmaceutics. 2023 Jul 20;15(7):1985. doi: 10.3390/pharmaceutics15071985, PMID 37514171, PMCID PMC10386213.
Gattani V, Dawre S. Development of favipiravir loaded PLGA nanoparticles entrapped in in-situ gel for treatment of COVID-19 via nasal route. J Drug Deliv Sci Technol. 2023 Jan;79:104082. doi: 10.1016/j.jddst.2022.104082, PMID 36530548, PMCID PMC9745979.
Ozkan B, Altuntas E, Unlu U, Dogan HH, Ozsoy Y, Çakır Koc R. Development of an antiviral ion-activated in situ gel containing 18β-Glycyrrhetinic acid: a promising alternative against respiratory syncytial virus. Pharmaceutics. 2023 Jul 31;15(8):2055. doi: 10.3390/pharmaceutics15082055, PMID 37631269, PMCID PMC10458153.
Chen S, Qiu Q, Wang D, She D, Yin B, Gu G. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence. J Control Release. 2022 Sep;349:565-79. doi: 10.1016/j.jconrel.2022.07.011, PMID 35835399.
Bakhrushina EO, Mikhel IB, Pyzhov VS, Demina NB, Krasnyuk II Jr, Krasnyuk II. Development of in situ intranasal system based on chitosan formate. Bull Exp Biol Med. 2023 Jan;174(3):337-40. doi: 10.1007/s10517-023-05704-6, PMID 36723743.
Mikhel IB, Bakhrushina EO, Petrusevich DA, Nedorubov AA, Appolonova SA, Moskaleva NE. Development of an intranasal in situ system for ribavirin delivery: in vitro and in vivo evaluation. Pharmaceutics. 2024 Aug 26;16(9):1125. doi: 10.3390/pharmaceutics16091125, PMID 39339163, PMCID PMC11435039.
Mikhel I, Bakhrushina E, Stepanova O, Prilepskaya S, Kosenkov D, Belyatskaya A. Ribavirin in modern antitumor therapy: prospects for intranasal administration. Curr Drug Deliv. 2024 Aug 26. doi: 10.2174/0115672018305548240614113451, PMID 39192644.
Tao Y, Zhang Y, Xia T, Lin N. Melt compounding of poly(lactic acid)-based composites: blending strategies, process conditions, and mechanical properties. Macromol Rapid Commun. 2024 Oct;45(20):e2400380. doi: 10.1002/marc.202400380, PMID 39012274.
Olkhov AA, Mastalygina EE, Ovchinnikov VA, Kurnosov AS, Popov AA, Iordanskii AL. Biological and oxidative degradation of ultrathin-fibrous nonwovens based on poly(lactic acid)/poly(3-hydroxybutyrate) blends. Int J Mol Sci. 2023 Apr 28;24(9):7979. doi: 10.3390/ijms24097979, PMID 37175689, PMCID PMC10178885.
Nyambura CW, Nance E, Pfaendtner J. Examining the effect of polymer extension on protein-polymer interactions that occur during formulation of protein-loaded poly(lactic acid-co-glycolic acid)-polyethylene glycol nanoparticles. Polymers (Basel). 2022 Nov 4;14(21):4730. doi: 10.3390/polym14214730, PMID 36365724, PMCID PMC9656384.
Woods SE, Tinkler JD, Bensabeh N, Pala M, Martin SJ, Martin Fabiani I. Temperature-responsive lactic acid-based nanoparticles by RAFT-mediated polymerization-induced self-assembly in water. ACS Sustain Chem Eng. 2023 Jun 26;11(27):9979-88. doi: 10.1021/acssuschemeng.3c01112, PMID 37448723, PMCID PMC10337250.
Capuana E, Lopresti F, Ceraulo M, La Carrubba V. Poly-l-lactic acid (PLLA)-based biomaterials for regenerative medicine: a review on processing and applications. Polymers (Basel). 2022 Mar 14;14(6):1153. doi: 10.3390/polym14061153, PMID 35335484, PMCID PMC8955974.
Cucoveica O, Stadoleanu C, Bertsch C, Triaud R, Condriuc IP, Atanase LI. Colloidal characteristics of poly(L-lactic acid)-b-poly (ε-caprolactone) block copolymer-based nanoparticles obtained by an emulsification/evaporation method. Polymers (Basel). 2024 Sep 28;16(19):2748. doi: 10.3390/polym16192748, PMID 39408458, PMCID PMC11479068.
Wanasathop A, Murawsky M, Li SK. Modification of small dissolution chamber system for long-acting periodontal drug product evaluation. Int J Pharm. 2022 Apr 25;618:121646. doi: 10.1016/j.ijpharm.2022.121646, PMID 35259441, PMCID PMC9136688.
Najahi Missaoui W, Arnold RD, Cummings BS. Safe nanoparticles: are we there yet? Int J Mol Sci. 2020 Dec 31;22(1):385. doi: 10.3390/ijms22010385, PMID 33396561, PMCID PMC7794803.
Kłusak A, Gazinska MA. Recent progress of poly(glycerol adipate)-based network materials toward tissue engineering applications. Front Bioeng Biotechnol. 2024 Sep 17;12:1447340. doi: 10.3389/fbioe.2024.1447340, PMID 39355275, PMCID PMC11442387.
Jacob PL, Brugnoli B, Del Giudice A, Phan H, Chauhan VM, Beckett L. Poly (diglycerol adipate) variants as enhanced nanocarrier replacements in drug delivery applications. J Colloid Interface Sci. 2023 Jul;641:1043-57. doi: 10.1016/j.jcis.2023.03.124, PMID 36996683.
Brugnoli B, Perna G, Alfano S, Piozzi A, Galantini L, Axioti E. Nanostructured poly-l-lactide and polyglycerol adipate carriers for the encapsulation of usnic acid: a promising approach for hepatoprotection. Polymers (Basel). 2024 Feb 3;16(3):427. doi: 10.3390/polym16030427, PMID 38337316, PMCID PMC10857334.
Taresco V, Tulini I, Francolini I, Piozzi A. Polyglycerol adipate-grafted polycaprolactone nanoparticles as carriers for the antimicrobial compound usnic acid. Int J Mol Sci. 2022 Nov 18;23(22):14339. doi: 10.3390/ijms232214339, PMID 36430814, PMCID PMC9693002.
Suksiriworapong J, Achayawat C, Juangrattanakamjorn P, Taresco V, Crucitti VC, Sakchaisri K. Modification of poly(glycerol adipate) with tocopherol and cholesterol modulating nanoparticle self-assemblies and cellular responses of triple-negative breast cancer cells to SN-38 delivery. Pharmaceutics. 2023 Aug 8;15(8):2100. doi: 10.3390/pharmaceutics15082100, PMID 37631315, PMCID PMC10459774.
Trifunovic J, Borcic V, Vukmirovic S, Vasovic V, Mikov M. Bile acids and their oxo derivatives: environmentally safe materials for drug design and delivery. Drug Chem Toxicol. 2017 Oct;40(4):397-405. doi: 10.1080/01480545.2016.1244680, PMID 27780364.
Nemati M, Fathi Azarbayjani A, Al-Salami H, Roshani Asl E, Rasmi Y. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics. Cell Biochem Funct. 2022 Aug;40(6):623-35. doi: 10.1002/cbf.3732, PMID 35830577.
Kaurav H, Tripathi M, Kaur SD, Bansal A, Kapoor DN, Sheth S. Emerging trends in bilosomes as therapeutic drug delivery systems. Pharmaceutics. 2024 May 23;16(6):697. doi: 10.3390/pharmaceutics16060697, PMID 38931820, PMCID PMC11206586.
Deng F, Bae YH. Effect of modification of polystyrene nanoparticles with different bile acids on their oral transport. Nanomedicine. 2023 Feb;48:102629. doi: 10.1016/j.nano.2022.102629, PMID 36410698, PMCID PMC9918699.
Moroishi K, Nakamoto M, Matsusaki M. Fabrication of molecular blocks with high responsiveness to the cancer microenvironment by ursodeoxycholic acid. Biomacromolecules. 2023 May 8;24(5):2369-79. doi: 10.1021/acs.biomac.3c00235, PMID 37053088.
Faustino C, Serafim C, Rijo P, Reis CP. Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents. Expert Opin Drug Deliv. 2016 Aug;13(8):1133-48. doi: 10.1080/17425247.2016.1178233, PMID 27102882.
Mondal D, Mandal RP, De S. Addressing the superior drug delivery performance of bilosomes-a microscopy and fluorescence study. ACS Appl Bio Mater. 2022 Aug 15;5(8):3896-911. doi: 10.1021/acsabm.2c00435, PMID 35924346.
Jones M, Ionescu CM, Walker D, Wagle SR, Kovacevic B, Chester J. Biguanide pharmaceutical formulations and the applications of bile acid-based Nano delivery in chronic medical conditions. Int J Mol Sci. 2022 Jan 13;23(2):836. doi: 10.3390/ijms23020836, PMID 35055022, PMCID PMC8775521.
Mooranian A, Raj Wagle S, Kovacevic B, Takechi R, Mamo J, Lam V. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6 mo diabetes preclinical study. Sci Rep. 2020 Jan 9;10(1):106. doi: 10.1038/s41598-019-53999-1, PMID 31919411, PMCID PMC6952395.
Gvoic M, Vukmirovic S, Al-Salami H, Mooranian A, Mikov M, Stankov K. Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. Pharm Dev Technol. 2021 Jul;26(6):617-33. doi: 10.1080/10837450.2021.1916032, PMID 33882793.
Zhou T, Liu Y, Lei K, Liu J, Hu M, Guo L. A “Trojan horse” strategy: the preparation of bile acid-modifying irinotecan hydrochloride nanoliposomes for liver-targeted anticancer drug delivery system study. Molecules. 2023 Feb 7;28(4):1577. doi: 10.3390/molecules28041577, PMID 36838565, PMCID PMC9963329.
Alghurabi H, Jassim Muhammad H, Tagami T, Ogawa K, Ozeki T. Optimization, cellular uptake, and in vivo evaluation of Eudragit S100-coated bile salt-containing liposomes for oral colonic delivery of 5-aminosalicylic acid. Int J Pharm. 2023 Dec 15;648:123597. doi: 10.1016/j.ijpharm.2023.123597, PMID 37952559.
Deng F, Bae YH. Bile acid transporter-mediated oral drug delivery. J Control Release. 2020 Nov 10;327:100-16. doi: 10.1016/j.jconrel.2020.07.034, PMID 32711025, PMCID PMC7606772.
Kim KS, Na K, Bae YH. Nanoparticle oral absorption and its clinical translational potential. J Control Release. 2023 Aug;360:149-62. doi: 10.1016/j.jconrel.2023.06.024, PMID 37348679.
Li H, Chen Y, Li Z, Li X, Jin Q, Ji J. Hemoglobin as a smart pH-sensitive nanocarrier to achieve aggregation enhanced tumor retention. Biomacromolecules. 2018 Jun 11;19(6):2007-13. doi: 10.1021/acs.biomac.8b00241, PMID 29498829.
Couroux P, Brkovic A, Vittitow JL, Israel RJ, Pamidi C, Patel J. A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Clin Transl Sci. 2022 Sep;15(9):2159-71. doi: 10.1111/cts.13350, PMID 35677972, PMCID PMC9468560.
Elalfy H, Besheer T, El-Mesery A, El-Gilany AH, Soliman MA, Alhawarey A. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021 May;93(5):3176-83. doi: 10.1002/jmv.26880, PMID 33590901, PMCID PMC8014583.
Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020 Nov 1;75(11):3366-72. doi: 10.1093/jac/dkaa331, PMID 32812051, PMCID PMC7529105.
Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van den Berg F. A novel inhaled dry-powder formulation of ribavirin allows for efficient lung delivery in healthy participants and those with chronic obstructive pulmonary disease in a phase 1 study. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19, PMID 32071044, PMCID PMC7179635.
Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R. The use of ribavirin as an anticancer therapeutic: will it go viral? Mol Cancer Ther. 2019 Jul;18(7):1185-94. doi: 10.1158/1535-7163.MCT-18-0666, PMID 31263027.
Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC. Discovery and preclinical characterization of XMT-1660, an optimized B7-H4-targeted antibody-drug conjugate for the treatment of cancer. Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786, PMID 37294948, PMCID PMC10477829.
Wong CW, Wong E, Metselaar JM, Storm G, Wong TT. Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. Drug Deliv Transl Res. 2022 Jan;12(1):7-14. doi: 10.1007/s13346-021-00912-x, PMID 33569720.
Published
How to Cite
Issue
Section
Copyright (c) 2025 MIKHEL I. B., TITOVA S. A., BAKHRUSHINA E. O., STEPANOVA O. I.; KRASNYUK I. I., SMOLYARCHUK E. A.; KRASNYUK I. I.
This work is licensed under a Creative Commons Attribution 4.0 International License.
